152 related articles for article (PubMed ID: 32382514)
1. Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy.
George B; Wen X; Mercke N; Gomez M; O'Bryant C; Bowles DW; Hu Y; Hogan SL; Joy MS; Aleksunes LM
Toxicol Rep; 2020; 7():571-576. PubMed ID: 32382514
[TBL] [Abstract][Full Text] [Related]
2. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.
George B; Joy MS; Aleksunes LM
Exp Biol Med (Maywood); 2018 Feb; 243(3):272-282. PubMed ID: 29231123
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS
Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072
[TBL] [Abstract][Full Text] [Related]
4. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.
George B; Wen X; Mercke N; Gomez M; O'Bryant C; Bowles DW; Hu Y; Hogan SL; Joy MS; Aleksunes LM
Clin Pharmacol Ther; 2017 Apr; 101(4):510-518. PubMed ID: 28002630
[TBL] [Abstract][Full Text] [Related]
5. Regulation of renal calbindin expression during cisplatin-induced kidney injury.
George B; Szilagyi JT; Joy MS; Aleksunes LM
J Biochem Mol Toxicol; 2022 Jul; 36(7):e23068. PubMed ID: 35403300
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
[TBL] [Abstract][Full Text] [Related]
7. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
Shinke H; Masuda S; Togashi Y; Ikemi Y; Ozawa A; Sato T; Kim YH; Mishima M; Ichimura T; Bonventre JV; Matsubara K
Cancer Chemother Pharmacol; 2015 Nov; 76(5):989-96. PubMed ID: 26407820
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin.
Ghadrdan E; Ebrahimpour S; Sadighi S; Chaibakhsh S; Jahangard-Rafsanjani Z
J Oncol Pharm Pract; 2020 Oct; 26(7):1643-1649. PubMed ID: 32046578
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of urinary kidney injury molecule-1 (Kim-1) as a biomarker for cisplatin-induced sub-chronic kidney injury.
Nan-Ya K; Kajihara M; Kojima N; Degawa M
J Appl Toxicol; 2015 Feb; 35(2):124-32. PubMed ID: 24737228
[TBL] [Abstract][Full Text] [Related]
10. Organic anion transporter 5 (Oat5) renal expression and urinary excretion in rats treated with cisplatin: a potential biomarker of cisplatin-induced nephrotoxicity.
Bulacio RP; Torres AM
Arch Toxicol; 2013 Nov; 87(11):1953-1962. PubMed ID: 23649842
[TBL] [Abstract][Full Text] [Related]
11. Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
Maeda A; Ando H; Ura T; Muro K; Aoki M; Saito K; Kondo E; Takahashi S; Ito Y; Mizuno Y; Fujimura A
Anticancer Res; 2017 Sep; 37(9):5235-5239. PubMed ID: 28870959
[TBL] [Abstract][Full Text] [Related]
12. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy.
Takashi M; Zhu Y; Miyake K; Kato K
Urol Int; 1996; 56(3):174-9. PubMed ID: 8860739
[TBL] [Abstract][Full Text] [Related]
13. Organic Anion Transporter 5 (Oat5) Urinary Excretion Is a Specific Biomarker of Kidney Injury: Evaluation of Urinary Excretion of Exosomal Oat5 after N-Acetylcysteine Prevention of Cisplatin Induced Nephrotoxicity.
Bulacio RP; Anzai N; Ouchi M; Torres AM
Chem Res Toxicol; 2015 Aug; 28(8):1595-602. PubMed ID: 26230185
[TBL] [Abstract][Full Text] [Related]
14. Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury.
Hosohata K; Ando H; Fujimura A
J Pharmacol Exp Ther; 2012 Jun; 341(3):656-62. PubMed ID: 22399813
[TBL] [Abstract][Full Text] [Related]
15. Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity.
Nishihara K; Masuda S; Shinke H; Ozawa A; Ichimura T; Yonezawa A; Nakagawa S; Inui K; Bonventre JV; Matsubara K
Biochem Pharmacol; 2013 Feb; 85(4):570-82. PubMed ID: 23291264
[TBL] [Abstract][Full Text] [Related]
16. Time course of renal proximal tubule injury, reversal, and related biomarker changes in rats following cisplatin administration.
McDuffie JE; Ma JY; Sablad M; Sonee M; Varacallo L; Louden C; Guy A; Vegas J; Liu X; La D; Snook S
Int J Toxicol; 2013 Jul; 32(4):251-60. PubMed ID: 23788329
[TBL] [Abstract][Full Text] [Related]
17. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury.
Yu Y; Jin H; Holder D; Ozer JS; Villarreal S; Shughrue P; Shi S; Figueroa DJ; Clouse H; Su M; Muniappa N; Troth SP; Bailey W; Seng J; Aslamkhan AG; Thudium D; Sistare FD; Gerhold DL
Nat Biotechnol; 2010 May; 28(5):470-7. PubMed ID: 20458317
[TBL] [Abstract][Full Text] [Related]
18. Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury.
Harrill AH; Lin H; Tobacyk J; Seely JC
Exp Biol Med (Maywood); 2018 Feb; 243(3):237-247. PubMed ID: 29110506
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys.
Chen Y; Dale Thurman J; Kinter LB; Bialecki R; Eric McDuffie J
Toxicol Appl Pharmacol; 2017 Dec; 336():66-74. PubMed ID: 29051111
[TBL] [Abstract][Full Text] [Related]
20. Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury.
Won AJ; Kim S; Kim YG; Kim KB; Choi WS; Kacew S; Kim KS; Jung JH; Lee BM; Kim S; Kim HS
Mol Biosyst; 2016 Jan; 12(1):133-44. PubMed ID: 26566257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
